Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
Vaccine
; 37(52): 7547-7559, 2019 12 10.
Article
en En
| MEDLINE
| ID: mdl-31607600
ABSTRACT
BACKGROUND:
To support vaccine decision-making we estimated from the societal perspective the potential health impact and costs averted through immunization with three vaccines - Haemophilus influenzae type b (Hib), pneumococcal conjugate vaccine (PCV) and rotavirus vaccine (RVV).METHODS:
Based on variability in disease burden, strength of health system and economic status, we selected four states in India Bihar, New Delhi, Maharashtra and Tamil Nadu. We used secondary data sources to estimate the number of under-5 deaths averted from Hib, pneumococcus and rotavirus in each state and back-calculated the total cases averted. We synthesized available data to estimate the disease burden, treatment cost, caretaker productivity loss and vaccine coverage in each state. A Delphi Survey and roundtable among Indian experts was conducted to reach consensus on model inputs.RESULTS:
By scaling up coverage of Hib, PCV and RVV, India could save over US$1 billion (uncertainty range US$0.9-US$2.4 billion) in economic benefits and avert more than 90,000 needless child deaths each year. An estimated US$1 billion (US$0.9-US$2 billion) or 88% of the total amount of cost savings would be attributable to lost productivity due to premature pneumococcal death. Another US$112.8 million (US$105-297 million), or 10% of the total cost would be accounted by costs related to loss of productivity due to disability as a result of these diseases. Treatment costs of Hib, pneumococcal disease and rotavirus gastroenteritis, would account for US$8.4 million (US$4-12 million) or <1% of the total costs of these diseases. Finally, caretaker productivity loss from seeking care would represent US$1.5 million (US$ 1-4.9 million). Cost savings varied by vaccine, coverage scenarios and states.CONCLUSIONS:
Hib, PCV and RVV vaccine introduction in India can result in immediate benefits to the government and households in terms of savings.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Análisis Costo-Beneficio
/
Programas de Inmunización
/
Vacunas contra Haemophilus
/
Vacunas Neumococicas
/
Vacunas contra Rotavirus
Tipo de estudio:
Health_economic_evaluation
/
Prognostic_studies
Límite:
Child, preschool
/
Humans
/
Infant
/
Newborn
País/Región como asunto:
Asia
Idioma:
En
Revista:
Vaccine
Año:
2019
Tipo del documento:
Article